Literature DB >> 24513799

Histologic grading of canine mast cell tumor: is 2 better than 3?

S Sabattini1, F Scarpa1, D Berlato2, G Bettini3.   

Abstract

Mast cell tumor (MCT) is a common canine cutaneous neoplasm with variable biological behavior. A 2-tier histologic grading system was recently proposed by Kiupel et al to reduce interobserver variation and eliminate prognostic uncertainty of the Patnaik system. This study compared the ability of these 2 grading systems to predict survival in a cohort of dogs with MCTs. However, surgical margins were unknown, and the risk of developing new/metastatic MCTs was not studied. Histologic grade was assessed according to both systems for 137 surgically resected cutaneous MCTs. The relationship between grade and survival was evaluated. According to the Patnaik system, 18 MCTs (13.1%) were classified as grade I, 83 (60.6%) as grade II, and 36 (26.3%) as grade III. Grade III was associated with a poorer prognosis (P < .001), but no significant difference between grades I and II was detected. Grading according to the Patnaik system was based on consensus grading among 3 pathologists, and interobserver variability was not considered. All grade I MCTs were low grade in the Kiupel system, and all grade III were high grade. Among grade II, 71 (85.6%) were low grade, and 12 (14.4%) were high grade, with a 1-year survival probability of 94% and 46%, respectively (P < .001). The 2-tier system had a high prognostic value and was able to correctly predict the negative outcomes of some grade II MCTs. Data also confirm that histologic grading cannot predict biological behavior of each MCT and should be supplemented with molecular methods for more accurate prognostication.
© The Author(s) 2014.

Entities:  

Keywords:  dog; histologic grade; mast cell tumor; prognosis; skin

Mesh:

Year:  2014        PMID: 24513799     DOI: 10.1177/0300985814521638

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  10 in total

1.  Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses.

Authors:  Nicholas J Roberts; Linping Zhang; Filip Janku; Amanda Collins; Ren-Yuan Bai; Verena Staedtke; Saurabh Saha; Shibin Zhou; Anthony W Rusk; David Tung; Maria Miller; Jeffrey Roix; Kristen V Khanna; Ravi Murthy; Robert S Benjamin; Thorunn Helgason; Ariel D Szvalb; Justin E Bird; Sinchita Roy-Chowdhuri; Halle H Zhang; Yuan Qiao; Baktiar Karim; Jennifer McDaniel; Amanda Elpiner; Alexandra Sahora; Joshua Lachowicz; Brenda Phillips; Avenelle Turner; Mary K Klein; Gerald Post; Luis A Diaz; Gregory J Riggins; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Chetan Bettegowda; David L Huso; Mary Varterasian
Journal:  Sci Transl Med       Date:  2014-08-13       Impact factor: 17.956

2.  Genomic profiling of canine mast cell tumors identifies DNA copy number aberrations associated with KIT mutations and high histological grade.

Authors:  Hiroyuki Mochizuki; Rachael Thomas; Scott Moroff; Matthew Breen
Journal:  Chromosome Res       Date:  2017-01-05       Impact factor: 5.239

3.  Evaluation of information presented within mast cell tumour histopathology reports in the United States: 2012-2015.

Authors:  Jennifer K Reagan; Laura E Selmic; Caroline Fallon; Elizabeth A Driskell; Laura D Garrett
Journal:  Vet Med Sci       Date:  2018-06-07

4.  Identification of two molecular subtypes in canine mast cell tumours through gene expression profiling.

Authors:  Lidia H Pulz; Camila N Barra; Pamela A Alexandre; Greice C Huete; Karine G Cadrobbi; Adriana T Nishiya; Silvio Henrique de Freitas; Heidge Fukumasu; Ricardo F Strefezzi
Journal:  PLoS One       Date:  2019-06-19       Impact factor: 3.240

5.  Analysis of risk factors for canine mast cell tumors based on the Kiupel and Patnaik grading system among dogs with skin tumors.

Authors:  Ana Luísa Martins; Fátima Faria Carvalho; João R Mesquita; Fátima Gärtner; Irina Amorim
Journal:  Open Vet J       Date:  2021-11-11

6.  Retrospective study of canine cutaneous tumors submitted to a diagnostic pathology laboratory in Northern Portugal (2014-2020).

Authors:  Irina Amorim; Fátima Gärtner; Ana Luísa Martins; Ana Canadas-Sousa; João R Mesquita; Patrícia Dias-Pereira
Journal:  Canine Med Genet       Date:  2022-02-25

7.  Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study.

Authors:  Shawna Klahn; Nikolaos Dervisis; Kevin Lahmers; Marian Benitez
Journal:  Vet Sci       Date:  2022-06-07

Review 8.  Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatment.

Authors:  Vanessa S Tamlin; Cynthia D K Bottema; Anne E Peaston
Journal:  Vet Med Sci       Date:  2019-10-24

9.  Beclin-1 is a novel predictive biomarker for canine cutaneous and subcutaneous mast cell tumors.

Authors:  Britta J Knight; Geoffrey A Wood; Robert A Foster; Brenda L Coomber
Journal:  Vet Pathol       Date:  2021-09-14       Impact factor: 2.221

10.  Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46).

Authors:  Thomas R De Ridder; Justine E Campbell; Cheryl Burke-Schwarz; David Clegg; Emily L Elliot; Samuel Geller; Wendy Kozak; Stephen T Pittenger; Jennifer B Pruitt; Jocelyn Riehl; Julie White; Melissa L Wiest; Chad M Johannes; John Morton; Pamela D Jones; Peter F Schmidt; Victoria Gordon; Paul Reddell
Journal:  J Vet Intern Med       Date:  2020-06-16       Impact factor: 3.175

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.